A novel MRI-biomarker candidate for Alzheimer's disease composed of regional brain volume and perfusion variables

European Journal of Neurology

Volumn 17, Issue 12, 2010, Pages 1437-1444

  Luckhaus, C ^a   Janner M ^a   Cohnen, M ^b   Fluss M O ^c   Teipel, S J ^d   Grothe, M ^d,e   Hampel, H ^f,g   Kornhuber, J ^h   Ruther E ⁱ   Peters, O ^j   Supprian, T ^a   Gaebel, W ^a   Modder U ^a   Wittsack, H J ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Lukaskrankenhaus GmbH   (Germany)

^c Department of Radiology and Nuclear Medicine   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

^f UNIVERSITY OF MUNICH   (Germany)

^g ADELAIDE AND MEATH HOSPITAL   (Ireland)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ UNIVERSITY OF GÖTTINGEN   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Alzheimer's disease; Biomarker; Biomarker combination; Composite marker; Mild cognitive impairment; Perfusion weighted magnetic resonance imaging; Volumetric magnetic resonance imaging

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; AREA UNDER THE CURVE; ARTICLE; BRAIN PERFUSION; BRAIN SIZE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; VOLUMETRY;

AGED; ALGORITHMS; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; ORGAN SIZE; REGIONAL BLOOD FLOW;

EID: 78649547334     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03038.x     Document Type: Article

References (23)

1. Luckhaus C. Cerebral grey and white matter changes in mild cognitive impairment and Alzheimer's disease. Eur J Neurol 2009; 16: 438-439.
2. Hampel H, Bürger K, Teipel SJ, et al. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008; 4: 38-48.
3. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49: 786-794.
4. Ewers M, Teipel SJ, Dietrich O, et al. Multicenter assessment of reliability of cranial MRI. Neurobiol Aging 2006; 27: 1051-1059.
5. Luckhaus C, Flüß MO, Wittsack H-J, et al. Detection of changed regional cerebral blood flow in mild cognitive impairment and early Alzheimer's dementia by perfusion-weighted magnetic resonance imaging. Neuroimage 2008; 40: 495-503.
6. Teipel SJ, Meindl T, Grinberg L, et al. Novel MRI techniques in the assessment of dementia. Eur J Nucl Med Mol Imaging 2008; 35(Suppl. 1): S58-S69.
7. Jessen F, Gür O, Block W, et al. A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 2009; 72: 1735-1740.
8. Luckhaus C, Cohnen M, Flüß MO, et al. The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. Psychiatry Res: Neuroimaging 2010; in press.
9. Fakhri GE, Kijewski MF, Johnson KA, et al. MRI-guided SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease. Arch Neurol 2003; 60: 1066-1072.
10. Borroni B, Premi E, Di Luca M, et al. Combined biomarkers for early Alzheimer disease diagnosis. Curr Med Chem 2007; 14: 1171-1178.
11. Kornhuber J, Schmidtke K, Frölich L, et al. Early and differential diagnosis of dementia and mild cognitive impairmentI: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord 2009; 27: 404-417.
12. Jellinger KA. Clinicopathological analysis of dementia disorders in the elderly - an update. J Alzheimers Dis 2006; 9(Suppl. 3): 61-70.
13. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
14. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
15. Ostergaard L, Weisskoff RM, Chesler DA, et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: mathematical approach and statistical analysis. Magn Reson Med Sci 1996; 36: 715-725.
16. Ostergaard L, Sorensen AG, Kwong KK, et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: experimental comparison and preliminary results. Magn Reson Med Sci 1996; 36: 726-736.
17. Leenders KL, Perani D, Lammertsma AA, et al. Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain 1990; 113: 27-47.
18. Pruessner JC, Li LM, Serles W, et al. Volumetry of hippocampus and amygdala with high-resolution MRI and three-dimensional analysis software: minimizing the discrepancies between laboratories. Cereb Cortex 2000; 10: 433-442.
19. Hixon JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548.
20. Jack CR Jr, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000; 55: 484-489.
21. Frank RA, Galsko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the Biological Markers Working Group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003; 24: 521-536.
22. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002; 359: 881-884.
23. Sackett DL, Haynes RB. The architecture of diagnostic research. Br Med J 2002; 324: 539-541.